Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah M Jones

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Clinical Pharmacokinetics|April 5, 2011
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modellingHannah M Jones, Iain B Gardner, Wendy T Collard, et al.
Oncotarget|October 4, 2017
Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancerLi Sun, Yajie Yin, Leslie H Clark, et al.
Journal of Pharmaceutical Sciences|April 12, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approachRagini Vuppugalla, Punit Marathe, Handan He, et al.
Journal of Pharmaceutical Sciences|April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasetsPatrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearanceBarbara J Ring, Jenny Y Chien, Kimberly K Adkison, et al.
Journal of Pharmaceutical Sciences|April 1, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distributionRhys Do Jones, Hannah M Jones, Malcolm Rowland, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 17, 2023
Development and application of a PBPK modeling strategy to support antimalarial drug developmentNada Abla, Eleanor Howgate, Karen Rowland-Yeo, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2011
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infectionThien-Duc Tran, David C Pryde, Peter Jones, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Clinical Pharmacokinetics|April 5, 2011
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modellingHannah M Jones, Iain B Gardner, Wendy T Collard, et al.
Oncotarget|October 4, 2017
Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancerLi Sun, Yajie Yin, Leslie H Clark, et al.
Journal of Pharmaceutical Sciences|April 12, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approachRagini Vuppugalla, Punit Marathe, Handan He, et al.
Journal of Pharmaceutical Sciences|April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasetsPatrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearanceBarbara J Ring, Jenny Y Chien, Kimberly K Adkison, et al.
Journal of Pharmaceutical Sciences|April 1, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distributionRhys Do Jones, Hannah M Jones, Malcolm Rowland, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 17, 2023
Development and application of a PBPK modeling strategy to support antimalarial drug developmentNada Abla, Eleanor Howgate, Karen Rowland-Yeo, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2011
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infectionThien-Duc Tran, David C Pryde, Peter Jones, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Pageof 10